Identifying specific B cells linked to a kidney disease called IgA nephropathy
Distinct Glycophenotypes with Abnormal Signaling Define a Subpopulation of B cells Responsible for Production of Galactose-Deficient IgA1, the Main Autoantigen in IgA Nephropathy
This study is looking at a special type of immune cell that makes a form of IgA linked to IgA nephropathy, to better understand how it contributes to kidney problems, with the hope of finding new treatments for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10978234 on NIH RePORTER |
What this research studies
This research investigates the role of certain B cells that produce a specific form of IgA, known as galactose-deficient IgA1, which is associated with IgA nephropathy. The study aims to understand how these B cells contribute to the disease and the formation of harmful immune complexes that can lead to kidney damage. By analyzing the characteristics of these B cells and their signaling pathways, researchers hope to uncover new insights into the mechanisms of IgA nephropathy. This could potentially lead to the development of targeted therapies for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with IgA nephropathy, particularly those showing signs of disease progression.
Not a fit: Patients with other forms of kidney disease or those without a diagnosis of IgA nephropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with IgA nephropathy, potentially slowing disease progression and improving kidney health.
How similar studies have performed: Previous research has shown promising results in understanding the autoimmune aspects of IgA nephropathy, suggesting that this approach could yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Reily, Colin Robert — University of Alabama at Birmingham
- Study coordinator: Reily, Colin Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.